Gujarat Themis Biosyn Limited has scheduled a meeting of its Board of Directors on Saturday, June 6, 2026, to evaluate and consider proposals for raising funds. The primary agenda involves exploring the issuance of equity shares or securities through various modes such as qualified institutions placement, preferential allotment, or a combination thereof.

The proposed fund raising initiative will be conducted in accordance with the applicable provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018. The company stated that the process is subject to obtaining the required regulatory and statutory approvals.

The intimation regarding the board meeting was submitted to the exchanges pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was made by Vineet Gawankar, Company Secretary & Compliance Officer of Gujarat Themis Biosyn Limited.

Gujarat Themis Biosyn Limited has expanded its international footprint by incorporating a wholly owned subsidiary, Themis Biosyn Ireland Private Limited, in Ireland on May 29, 2026. The strategic move marks the company's entry into the European market, with the new entity operating within the pharmaceutical industry. Gujarat Themis Biosyn holds 100% of the shareholding in the subsidiary, ensuring complete control over its operations.

The disclosure was made to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The subsidiary was registered with a share capital of 1,00,000 Euro. The Business registration extract for the new entity was received on the same date as its incorporation.

Details regarding the new subsidiary were provided in an annexure to the regulatory filing. The document clarified that the incorporation does not constitute a related party transaction, nor does it involve any interest from the promoter, promoter group, or other group companies. Consequently, specific details regarding acquisition costs, consideration, and regulatory approvals were noted as not applicable.

Subsidiary Details

The following table outlines the key particulars of the newly incorporated entity:

The filing was signed by Dinesh S. Patel, Chairman & Director of Gujarat Themis Biosyn Limited. The information has been submitted to BSE Limited and the National Stock Exchange of India Limited for public dissemination.